Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading...
MaxCyte, Inc. 10 October 2024 MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer Rockville, MD, Oct. 10, 2024 - MaxCyte...
MaxCyte, Inc. 03 October 2024 MaxCyte, Inc. ("MaxCyte" or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD, October 3...
MaxCyte, Inc. 01 October 2024 MaxCyte, Inc. ("MaxCyte" or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD, October 1...
MaxCyte, Inc. 01 October 2024 MaxCyte, Inc. ("MaxCyte" or the "Company") Total Voting Rights ROCKVILLE, MD, October 1, 2024: MaxCyte...
MaxCyte, Inc. 27 September 2024 TR-1: Notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and...
MaxCyte, Inc. 20 September 2024 TR-1: Notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and...
MaxCyte Inc on Monday celebrated the signing of a strategic platform license agreement with Kamau Therapeutics, a cli ...
MaxCyte, Inc. 16 September 2024 TR-1: Notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and...
MaxCyte, Inc. 16 September 2024 MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell...
ROCKVILLE, Md. and SOUTH SAN FRANCISCO, Calif., Sept. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq:...
MaxCyte, Inc. 06 September 2024 MaxCyte, Inc. ("MaxCyte" or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD, September...
ROCKVILLE, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading...
MaxCyte, Inc. 03 September 2024 MaxCyte, Inc. ("MaxCyte" or the "Company") Total Voting Rights ROCKVILLE, MD, September 3, 2024: MaxCyte...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관